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Purpose: Tc-99m-MIBI accumulates in only viable cells. In patients with bone and soft tissue 
sarcomas, preoperative chemotherapy is essential and the early prediction of the tumor response to 
chemotherapy would be beneficial for the planning of treatment strategy. The purpose of this study 
was to assess whether the change of Tc-99m-MIBI image from pre-chemotherapy to the early to 
middle of the chemotherapy can predict final histopathological tumor response as accurately as the 
change of the image after completion of chemotherapy. 
Methods: Seventy-three patients with bone and soft tissue sarcomas underwent Tc-99m-MIBI 
scintigraphy before chemotherapy and at least 2 times after the second or third or fifth 
chemotherapy. The change of the tracer uptake (∆UR) and perfusion (∆PI) from pre-chemotherapy 
to post-chemotherapy were compared with histologic response. 
Results: The sensitivity, specificity, and accuracy for the prediction of effective chemotherapy in 
∆PI were 88%, 83%, 85% after 2nd, 85%, 72%, 78% after 3rd, and 81%, 71%, 76% after 5th 
chemotherapy, and those in ∆UR were 88%, 83%, 85% after 2nd, 85%, 92%, 89% after 3rd, and 
94%, 77%, 85% after 5th chemotherapy, respectively. The area under the receiver operator 
characteristic curve of the ∆PI after 2nd, 3rd, and 5th chemotherapy were similarly good (0.842, 
0.858, 0.811, respectively) and those of ∆UR were similarly excellent (0.915, 0.936, 0.931, 
respectively). 
Conclusion: In patients with bone and soft tissue sarcomas, the change of Tc-99m-MIBI image 
from pre-chemotherapy to early to middle of chemotherapy can predict the final histopathological 
tumor response to chemotherapy as accurately as the change of Tc-99m-MIBI image from 
pre-chemotherapy to the completion of the preoperative chemotherapy. 
 Key Words: bone and soft tissue sarcoma; Tc-99m-MIBI; preoperative chemotherapy; treatment 
monitoring;  osteosarcoma; Ewing’s sarcoma. 
 
Introduction 
   In patients with bone and soft tissue sarcomas, the combination of aggressive chemotherapy 
before surgical intervention and limb-sparing surgery permits excellent quality of life and dramatic 
improvement of the prognosis 1. The accurate evaluation of chemotherapeutic effects is essential for 
proper treatment strategy because a good response to preoperative chemotherapy is crucial to 
limb-sparing surgery.2-4 In addition, early prediction of the tumor response to chemotherapy during 
preoperative chemotherapy would be beneficial for the planning of treatment strategy. Furthermore, 
noninvasive and quantitative assessment of tumor response to chemotherapy may provide 
prognostic information that could be useful for subsequent patient’s management, because good 
pathological response to chemotherapy has been proved to be a predictor of good prognosis in 
osteosarcoma.5-6 
   Recently, there has been growing interest in using Tc-99m-hexakis-2-methoxyisobutylisonitrile 
(MIBI), used as a myocardial perfusion imaging agent, for tumor imaging including bone and 
soft-tissue tumors.7-9 As a tumor imaging agent Tc-99m-MIBI has unique characteristics. 
Administration of high radionuclide activity permits radionuclide angiography, which provides 
information of tumor blood flow. After Tc-99m-MIBI accumulation to the tumor, the degree of 
washout of the tracer from the tumor reflects P-glycoprotein overexpression which implies 
multidrug resistance.10,11 In addition, several studies have revealed that the change of Tc-99m-MIBI 
uptake from pre-chemotherapy to post-chemotherapy could reflect the chemotherapeutic effect in 
patients with bone sarcomas.8,12-14 However, there has been no report that investigated whether 
Tc-99m-MIBI imaging performed during preoperative chemotherapy as well as performed after the 
completion of the chemotherapy can equally well predict final tumor response to preoperative 
chemotherapy. 
   Therefore, the purpose of this study was to assess whether the combination of Tc-99m-MIBI 
scintigraphy performed before and in the early to middle of the preoperative chemotherapy can 
predict final histopathological tumor response to chemotherapy without deterioration of the 
diagnostic accuracy compared with the combination of the imaging performed before chemotherapy 
and after final cycle of chemotherapy in bone and soft tissue sarcomas. 
 
MATERIALS AND METHODS 
Patients 
   Seventy three patients (54 men and 19 women; age range, 7 to 74 years, average age, 28.8 ± 18 
years) with various bone and soft-tissue sarcomas proven pathologically in specimens obtained by 
biopsy at pretreatment and operation after chemotherapy were recruited in this study, and all gave 
informed consent to participate in this study. There were 36 osteosarcomas (28 osteoblastic type, 5 
chondroblastic type, 2 fibroblastic type, and 1 small cell osteosarcoma), 7 malignant fibrous 
histiocytomas (5 pleomorphic type, 1 spindle cell type, 1 myxoid type), 7 liposarcomas (6 myxoid 
liposarcoma and 1 pleomorphic liposarcoma), 6 Ewing sarcomas, 4 synovial sarcomas, 3 
chondrosarcomas (2 mesenchymal chondrosarcoma and 1 extraskeletal myxoid chondrosarcoma), 3 
rhabdomyosarcomas, 2 angiosarcomas, 2 leiomyosarcomas, 1 malignant schwannoma, 1 alveolar 
soft part sarcoma, and 1 malignant giant cell tumor. Sixty-three lesions were located in the 
extremities, 5 were located in pelvic area, 2 were located at shoulder, 2 were in ribs, 1 was at axilla. 
Forty-six tumors were located in bone and 27 were in soft tissue. 
   Patients received 5 cycles of preoperative chemotherapy at intervals of 2~3 weeks. In each 
chemotherapy cycle, cisplatin (120 mg / m2) was continuously infused through the intra-arterial 
catheter for 1 to 2 hours followed by 48 hours continuous infusion of doxorubicin (60 mg / m2) and 
72 hours infusion of caffeine.15,16 
Study Protocol and Tc-99m-MIBI Scintigraphy 
   The study protocol is shown in figure 1. All patients underwent imaging with Tc-99m-MIBI at 
least 3 times. Before chemotherapy all patients underwent the imaging with Tc-99m-MIBI (n=73), 
and after 1 week of the completion of the 2 (n=20) or 3 (n=69) or 5 cycles (n=66) of chemotherapy, 
same radionuclide imaging procedures were performed. After the completion of the 5 cycles of 
chemotherapy surgical operation was performed. Then the scintigraphic predictive power for the 
chemotherapeutic effect was assessed in comparison with the results of the postoperative 
histological examination. 
   Radionuclide angiography was performed after bolus injection of 600 - 740 MBq (16.2 – 20 mCi) 
of Tc-99m-MIBI with a gamma camera equipped with a low energy high-resolution parallel-hole 
collimator. Data were acquired every 2 sec for 2 min.  Then, planar 2-min Tc-99m-MIBI image of 
the lesion was obtained at 15 min after radionuclide administration with 256 x 256 matrices. 
Image Analysis 
   In the quantitative analysis of the pre-chemotherapeutic image, a manual region of interest (ROI) 
was set on the lesion and an automatically generated symmetrical ROI was set on the contralateral 
normal area as a background. When tumor Tc-99m-MIBI uptake is weak, the ROI of the tumor was 
delineated carefully to cover the whole lesion by referring to the computed tomography or magnetic 
resonance image. In the analysis of the images obtained after 2, 3 or 5 cycles of chemotherapy, 
tumor ROI was newly set to cover the whole lesion as described above. Therefore, ROI size was 
changed depending on the size of the tumor. When the tumor uptake of radionuclide disappeared 
completely the same ROI delineated at prechemotherapy was applied to calculate the indices. 
Tc-99m-MIBI uptake ratio (UR) were calculated by dividing the count density of the lesion by that 
of the background ROI. For the prediction of the chemotherapeutic effect, the percent reduction of 
uptake ratio (∆UR) was calculated as follows: 
∆UR (%) = 100[(prechemotherapy UR - postchemotherapy UR) / prechemotherapy UR] 
The perfusion index (PI) was obtained by radionuclide angiography with Tc-99m-MIBI.  Using the 
same ROI set to calculate the uptake ratio, the time-activity curve of each ROI was generated, and 
the PI was determined by dividing the peak count of the arterial phase of the lesion by that of the 
background ROI.  When a peak count was not obtained, the time activity curve always showed a 
shoulder point, which was the flexion point between the rapid count increase due to the arterial 
phase and steady state or gradual count increase due to Tc-99m-MIBI accumulation to the lesion 
and normal tissue.  Therefore, the count of the flexion point of the time activity curve was used to 
calculate the PI. Percent reduction of perfusion index (∆PI) was also calculated to predict the 
response to chemotherapy by the following formula: 
∆PI (%) =100[(prechemotherapy PI - postchemotherapy PI) / prechemotherapy PI] 
Assessment of the Chemotherapeutic effect by Histopathology 
  After 5 cycle of chemotherapy surgical resection of the tumor was performed. Post-operative 
histological assessment was performed in all patients to evaluate the response of the tumor to 
chemotherapy.  Histological grading of the effect of chemotherapy was determined based on the 
degree of viable cellularity and necrosis in the largest slice of the resected tumor.5 Grade IV (100% 
necrosis) and grade III (90%≤ to <100% necrosis) response were defined as good response to 
chemotherapy (effective chemotherapy).  Grade II (50%< to <90% necrosis) and Grade I ( ≤50% 
necrosis) responses were defined as poor response. 
Statistics 
   Values are expressed as the mean ± SD. Differences in PIs and URs, and ∆PIs and ∆URs between 
good and poor response were analyzed by student t-test using the software JMP-5.0.1J for 
Macintosh computer. To appraise the discrimination abilities of the ∆PIs and ∆URs for the 
prediction of effective chemotherapy, receiver operator characteristic (ROC) curves were generated, 
and the areas under the curves (Az) were calculated. The differences between the areas under the 2 
ROC curves were examined using the 1-tailed paired t test.17,18 The optimal cutoff levels were 
identified as each index value minimizing the total number of false results.19 P < 0.05 was 
considered statistically significant. ROC analysis was performed using the software ROCKIT 0.9B 
(free software developed by Charles E. Metz, PhD for Macintosh computer).17,18 
 
RESULTS 
   Post-operative histological examination of the resected tumors demonstrated good response in 33 
patients and poor response in 40 patients. Good responders included 20 osteosarcomas, 3 malignant 
fibrous histiocytomas, 2 liposarcomas, 3 Ewing sarcomas, 1 synovial sarcomas, 1 
rhabdomyosarcoma, 1 leiomyosarcoma, 1 malignant schwannoma, and 1 malignant giant cell tumor. 
Poor responders included 16 osteosarcomas, 4 malignant fibrous histiocytomas, 5 liposarcomas, 3 
Ewing sarcomas, 3 synovial sarcomas, 3 chondrosarcomas, 2 rhabdomyosarcomas, 2 angiosarcomas, 
1 leiomyosarcoma, and 1 alveolar soft part sarcoma. 
   All lesions showed significant tracer uptake. Accordingly, ROIs could be set without difficulty. In 
2 patients after 3 cycles of chemotherapy and in 1 patient after 5 cycles of chemotherapy, PI of 
Tc-99m-MIBI was not calculated because of poor bolus infusion of the radionuclide. 
   Before preoperative chemotherapy, there are no differences between the patients with good and 
poor response in PI (3.97 ± 2.51 and 3.38 ± 1.68, respectively, P=ns)) and UP (2.83 ± 0.93 and 2.74 
± 1.38, respectively, P=ns). After 2, 3, and 5 cycles of chemotherapy, in patients with good 
response, PI decreased to 1.81 ± 0.61 (P<0.01), 1.97 ± 1.25 (P<0.01), and 1.51 ± 0.76 (P<0.01), 
respectively, and UR also decreased to 1.56 ± 0.46 (P<0.01), 1.58 ± 0.51 (P<0.01), and 1.34 ± 0.46 
(P<0.01), respectively. In patients with poor response, after 2, 3, and 5 cycles of chemotherapy, 
both PI (3.88 ± 2.17, 3.70 ± 2.77, 2.92 ± 2.48, respectively) and UR (2.64 ± 1.14, 2.61 ± 1.22, 2.19 
± 1.02, respectively) did not change significantly. Consequently, after 2, 3, and 5 cycles of 
chemotherapy, good responders demonstrated lower PI (P<0.05, P<0.01, P<0.01, respectively) and 
lower UR (P<0.05, P<0.01, P<0.01, respectively) than poor responders. 
   The ∆PI after 2 cycles of chemotherapy in patients with good and poor response were 36 ± 23% 
and -12 ± 42% (P < 0.01), respectively (Fig. 2A). The ∆PIs after 3 and 5 cycles of chemotherapy in 
patients with good and poor response were 45 ± 27% and -8.3 ± 50% (P < 0.0001), respectively 
(Fig. 2B), and 55 ± 22% and 19 ± 37% (P < 0.0001), respectively (Fig. 2C). The ∆UR obtained 
after 2 cycles of chemotherapy in patients with good and poor response were 34 ± 16% and -8 ± 
32% (P=0.005), respectively (Fig. 3A), and those after 3 and 5 cycles of chemotherapy were 43 ± 
14% and -0.7 ± 39% (P < 0.0001), respectively (Fig. 3B) and 52 ± 13% and 15 ± 27% (P < 0.0001), 
respectively (Fig. 3C). 
   The ROC curves for the predictability of effective chemotherapy of the ∆PI and ∆UR obtained 
after 2, 3, and 5 cycles of chemotherapy are shown in figure 4. The Az of the ∆PI after 2, 3, and 5 
cycles of chemotherapy were 0.842, 0.858, and 0.811, respectively and there were no significant 
differences among the values (P=0.13~0.49). The Az of the ∆UR after 2, 3, and 5 cycles of 
chemotherapy were 0.915, 0.936, and 0.931, respectively and there were no significant differences 
among the values (P=0.15~0.31). When Az of the ∆PI and ∆UR in each cycles of chemotherapy is 
compared, Az of the ∆PI is lower than that of ∆UR in every scintigraphic timing but only 
statistically significant after 5 cycles of chemotherapy (2 cycle: P= 0.16, 3 cycle: P= 0.063, 5 cycle: 
P= 0.0031). 
   The optimal thresholds obtained by ROC analysis, sensitivity, specificity, accuracy, positive and 
negative predictive values of each index obtained after 2, 3, and 5 cycles after chemotherapy were 
summarized in Table 1. The accuracy of ∆PI after 2, 3, and 5 cycles after chemotherapy was 85%, 
78%, 76%, respectively, and that of ∆UR after 2, 3, and 5 cycles after chemotherapy was 85%, 89%, 
85%, respectively. 
   On the contrary, the accuracy of PI after 2, 3, and 5 cycles after chemotherapy was 70%, 69%, 
70%, respectively, and that of UR after 2, 3, and 5 cycles after chemotherapy was 70%, 69%, 72%, 
respectively. 
   Representative cases are shown in Fig 5 (good responder) and Fig 6 (poor responder). 
 
DISCUSSION 
   The present study demonstrated that the combination of the Tc-99m-MIBI scintigraphies 
performed before chemotherapy and in the early to middle of preoperative-chemotherapy (after the 
2nd and 3rd cycle) as well as after final cycle of chemotherapy (5th cycle) can accurately predict 
the final response to chemotherapy which was proved by histopathology after 5 cycles of 
chemotherapy and operation. Based on the ROC analysis, both the performance of ∆PI and ∆UR for 
the prediction of the chemotherapeutic effect was similarly good after 2, 3 and 5 cycle of 
chemotherapy. Therefore accurate prediction of the chemotherapeutic effect can be possible during 
early to middle of chemotherapy. However, when ∆PI and ∆UR was compared, predictive 
performance of ∆UR tended to be better than that of ∆PI after 2 and 3 cycle of therapy and 
significantly better after the final cycle of preoperative chemotherapy. 
   On the contrary the diagnostic accuracies for the prediction of chemotherapeutic effect of PI and 
UR itself after 2, 3, and 5 cycles of chemotherapy were 69% ~ 72%, and those were inferior to that 
of ∆PI and ∆UR (76% ~ 89%, Table 1). 
   Tc-99m-MIBI has been introduced primarily as a myocardial perfusion imaging agent to replace 
Tl-201. Tc-99m-MIBI has lipophilic cationic properties, accumulating largely in mitochondria by 
its negative trans-membrane potential. Moreover, its accumulation depends on the cell viability and 
metabolic status in myocardial cells.20-22 Like myocardial cells, human carcinoma cells accumulate 
Tc-99m-MIBI by depending on the mitochondria and plasma membrane potentials.23,24 In addition, 
radionuclide angiography with sufficient dose at the administration of the tracer can permit 
evaluation of the tumor blood flow. Accordingly, Tc-99m-MIBI scintigraphy provide integrated 
information of the tumor blood flow and tracer uptake which reflect tumor viability and metabolic 
status. 
   For the evaluation of the tumor response to preoperative chemotherapy, several modalities are 
performed such as CT, MRI, angiography, ultrasonography, and radionuclide imaging. 
Conventional angiography with contrast medium can observe tumor blood flow. Although, it can 
offer precise morphology of tumor vasculature, quantification of the tumor blood flow is somewhat 
difficult compared to radionuclide angiography. CT and MRI can precisely evaluate the tumor size. 
However, they cannot evaluate tumor viability and metabolic status so precisely even with contrast 
enhancement because fibrotic change, inflammatory change, or granulation tissue secondary to 
tumor necrosis after chemotherapy could be enhanced. Dynamic contrast-enhanced MRI provides 
information about tissue perfusion, vascular permeability, micro-vessel density 25 and may 
differentiate viable tumor tissue from reparative tissue. Several parameters by mathematical 
quantification of the dynamic data permit prediction of the chemotherapeutic response after the 
completion of the preoperative chemotherapy.26 However, early prediction of chemotherapeutic 
effect by dynamic MRI remains to be elucidated.27,28 The parameter calculated by dynamic MRI 
might mainly reflect tumor perfusion and might be similar to that obtained by radionuclide 
angiography with Tc-99m-labeled tracers.28 Color Doppler ultrasound also could predict 
chemotherapeutic response by assessing the change of tumor blood supply and intratumoral blood 
flow after chemotherapy.29 The method is relatively simple but further evaluation would be 
warranted including the issue of the reproducibility. Several FDG-PET studies has also 
demonstrated the efficacy in the prediction of the effect of chemotherapy at the end of preoperative 
chemotherapy,30-34 however, sensitive FDG accumulation in chemotherapy induced inflammation or 
therapy related fibrous tissue has impaired the diagnostic accuracy in some cases.31-33 Unfortunately, 
there has been no report in terms of the early prediction of preoperative chemotherapy using FDG 
PET in bone and soft tissue sarcomas. 
   In a previous study with 12 osteosarcoma patients, reduction of Tc-99m-MIBI uptake after 
completion of chemotherapy roughly correlated to the histological response.35 Another studies with 
28 bone sarcoma patients and 68 patients with bone and soft tissue sarcoma demonstrated good 
correlation between the reduction of Tc-99m-MIBI uptake after 3 or 4 cycles of chemotherapy 
and % necrosis of the tumor 36 and good predictability of tumor response to chemotherapy.14 In the 
present study, in both bone and soft tissue sarcomas, reduction of tumor perfusion and 
Tc-99m-MIBI uptake in the early to middle of chemotherapy as well as after final cycle of 
chemotherapy can predict the final histological tumor response to chemotherapy. In the clinical 
setting, a precise diagnostic method for the assessment of the chemotherapeutic effect at the earliest 
possible time after initiation of chemotherapy would be preferable. Our current study demonstrated 
that early imaging could permit prices estimation of chemotherapeutic effect after 2 or 3 cycle of 
preoperative chemotherapy as accurately as after final cycle of therapy, suggesting that the method 
may have an impact on modification of neoadjuvant chemotherapy protocol, on patient selection for 
the performance and timing of limb-sparing surgery, and on the selection of postoperative 
chemotherapy regimens. 
   MIBI has been proved to be the one of the substrates of P-glycoprotein, a product of the human 
multidrug resistance gene and multidrug resistance related protein.37,38 It has been proved that 
Tc-99m-MIBI once accumulated in tumor cells would be washed out from the cells by 
P-glycoprotein and the delayed Tc-99m-MIBI uptake was related to P-glycoprotein expression, 
while early uptake was not.10 Accordingly, early Tc-99m-MIBI uptake seems to reflect tumor 
viability more properly than delayed uptake. Therefore, as a marker of tumor viability, we analyzed 
only Tc-99m-MIBI uptake in early image obtained at 15 min after tracer injection. 
   For the assessment of tumor perfusion and Tc-99m-MIBI uptake, tumor ROI was set in each 
image before and after chemotherapy independently, i.e., new ROI was delineated after 
chemotherapy if tumor size changed to cover whole tumor more precisely instead of using the same 
ROI used before chemotherapy. This is because we assessed the histologic grading of 
chemotherapeutic effect based on the degree of cellularity and necrosis in the largest slice of the 
resected tumor as a gold standard of tumor response to chemotherapy. Accordingly ROI 
modification along with the change of the tumor size may reflect more precisely the tumor viability 
based on the histopathological examination. 
   Possible drawbacks of Tc-99m-MIBI include its high uptake by the liver and excretion to the 
intestine and urinary system, which interfere with abdominal and pelvic evaluation. However, 
lesions of the extremities, where most bone and soft tissue sarcomas are found, are unaffected by 
these issues. 
   Since there was a great variety of tumor types included in this study, there was some dispersion in  
Tc-99m-MIBI tumor uptake. However, since the tumor Tc-99m-MIBI uptake reflects tumor 
viability and metabolic status, the degree of the change of tumor viability by chemotherapy might 
be reflected similarly to the change of Tc-99m-MIBI uptake among various tumor types. 
 
CONCLUSION 
   The study demonstrates that the change in tumor perfusion and Tc-99m-MIBI uptake from 
pre-chemotherapy to early to middle of preoperative chemotherapy as well as to the final cycle of 
chemotherapy is highly predictive of histopathological tumor response to chemotherapy in bone and 
soft tissue sarcomas. This imaging technique, especially in ∆UR, might be a beneficial method in 
patient care and in elaborating treatment strategy during preoperative chemotherapy. 
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Study protocol. Tc-99m-MIBI scintigraphy was performed before chemotherapy in all patients, and 
at least 2 scintigraphic studies were performed after 2, 3, or 5 cycle of chemotherapy. The change of 
perfusion index and uptake ratio from prechemotherapy to after each chemotherapy cycle were 
compared to the histopathological response to chemotherapy. 
 
FIGURE 2 
Percent reduction of perfusion index (PI) obtained from radionuclide angiography with 
Tc-99m-MIBI after 2 cycle (A), 3 cycle (B), and 5 cycle (C) of chemotherapy in patients with good 
response and poor response. Horizontal dashed line indicates threshold line derived from receiver 
operator characteristic curve analysis that minimized the total number of false results. 
 
FIGURE 3 
Percent reduction of Tc-99m-MIBI uptake ratio (UR) after 2 cycle (A), 3 cycle (B), and 5 cycle (C) 
of chemotherapy in patients with good response and poor response. Horizontal dashed line indicates 
threshold line derived from receiver operator characteristic curve analysis that minimized the total 
number of false results. 
 
FIGURE 4 
Receiver operator characteristic (ROC) curve analysis for the prediction of tumor response to 
chemotherapy using ∆PI and ∆UR. The areas under the ROC curve (Az) of the percent change of 
perfusion index (∆PI) at after 2 cycle (0.842), 3 cycle (0.858), and 5 cycle (0.811) of chemotherapy 
were similar (A). The Az of the percent change of Tc-99m-MIBI uptake ratio (∆UR) at after 2 cycle 
(0.915), 3 cycle (0.936), and 5 cycle (0.931) of chemotherapy were also similar (B). 
 
FIGURE 5 
A 50-year-old female with pleomorphic malignant fibrous histiocytoma of the left shoulder. Before 
chemotherapy, radionuclide angiography with Tc-99m-MIBI demonstrated marked increase in 
tumor blood flow. Anterior chest image obtained 15min after the tracer injection showed intense 
accumulation of Tc-99m-MIBI in the left shoulder. After 2 cycles of chemotherapy, tumor blood 
flow and Tc-99m-MIBI uptake decreased dramatically. After 3 and 5 cycles of chemotherapy, no 
significant increase in tumor blood flow and Tc-99m-MIBI uptake was observed. All these findings 
implied a good response to chemotherapy. Wide resection of tumor was performed after 5 cycles of 
chemotherapy. Pathological study of the resected tumor specimen revealed no viable tumor cells. 
 
FIGURE 6 
A 16-year-old male with osteosarcoma of the right distal femur. Before chemotherapy, radionuclide 
angiography with Tc-99m-MIBI demonstrated marked increase in tumor blood flow and intense 
Tc-99m-MIBI uptake. After 2, 3, and 5 cycles of chemotherapy, tumor blood flow and tumor 
uptake of Tc-99m-MIBI were still increased. All these findings implied a poor response to 
chemotherapy. After 5 cycles of chemotherapy, resection of the tumor was performed and the 
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